映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09606 映恩生物-B

未开盘 04-23 16:08:51

218.600

-1.000

-0.46%

最高233.800	最低212.800	成交量69.96万
今开231.000	昨收219.600	日振幅9.56%
总市值186.76亿	流通市值186.76亿	总股本8,544万
成交额1.55亿	换手率0.82%	流通股本8,544万
市净率-8.65	ROE--	每股收益-139.80
52周最高234.600	52周最低178.800	市盈率-1.56
股息0.00	股息收益率0.00	ROA-6.51%

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":218.6,"timestamp":1745395731019,"preClose":219.6,"halted":0,"volume":699640,"delay":0,"floatShares":85436500,"shares":85436464,"eps":-139.8025303133293,"marketStatus":"未开盘","change":-1,"latestTime":"04-23 16:08:51","open":231,"high":233.8,"low":212.8,"amount":155318286,"amplitude":0.095628,"askPrice":218.8,"askSize":2200,"bidPrice":218.6,"bidSize":300,"shortable":0,"etf":0,"ttmEps":-139.80254096055063,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745458200000},"marketStatusCode":0,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":219.6,"openAndCloseTimeList":[[1745371800000,1745380800000],[1745384400000,1745395200000]],"volumeRatio":0.18268465949262067,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09606","defaultTab":"news","newsList":[{"id":"2529532107","title":"映恩生物-B04月22日主力净流入272万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529532107","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529532107?lang=zh_cn&edition=full","pubTime":"2025-04-22 16:15","pubTimestamp":1745309744,"startTime":"0","endTime":"0","summary":"04月22日, 映恩生物-B股价涨9.80%，报收219.60元，成交金额2.91亿元，换手率1.54%，振幅14.50%，量比0.00。映恩生物-B今日主力资金净流入272万元，上一交易日主力净流出591万元。该股近5个交易日上涨131.71%，主力资金累计净流出568万元；近20日主力资金累计净流出568万元，其中净流出天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422170825a6c38aad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422170825a6c38aad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606"],"gpt_icon":0},{"id":"2529315118","title":"映恩生物-B午后涨超15% 国泰海通给予“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2529315118","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529315118?lang=zh_cn&edition=full","pubTime":"2025-04-22 13:22","pubTimestamp":1745299320,"startTime":"0","endTime":"0","summary":"　　映恩生物-B早盘涨超16%，高见234港元，创上市新高。午后上涨15.20%，现报230.80港元，成交额1.97亿港元。　　公开资料显示，映恩生物是全球抗体偶联药物领域的关键领跑者，致力于为癌症和自身免疫性疾病等患者研发ADC创新药物。　　国泰海通发布研报称，公司聚焦ADC新药研发，产品达成多项License-out对外授权。首次覆盖，给予“增持”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-22/doc-inetzkuy0978708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09606"],"gpt_icon":1},{"id":"1118159098","title":"异动解读 | 映恩生物-B盘中大涨15%，ADC新药研发引发市场热捧","url":"https://stock-news.laohu8.com/highlight/detail?id=1118159098","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118159098?lang=zh_cn&edition=full","pubTime":"2025-04-22 12:46","pubTimestamp":1745297189,"startTime":"0","endTime":"0","summary":"映恩生物-B今日盘中大涨15.00%，股价一度触及232.8港元的历史新高，引发市场广泛关注。截至盘中，该股报226.4港元，成交额达1.75亿港元。映恩生物是全球抗体偶联药物领域的关键领跑者，专注于为癌症和自身免疫性疾病等患者研发ADC创新药物。国泰海通发布的最新研报进一步推动了映恩生物-B的股价上涨。该券商看好公司聚焦ADC新药研发的战略，以及产品达成的多项对外授权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09606"],"gpt_icon":0},{"id":"1194208776","title":"异动解读 | 映恩生物-B盘中大涨15%，ADC新药研发进展及券商看好推动股价创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1194208776","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194208776?lang=zh_cn&edition=full","pubTime":"2025-04-22 12:46","pubTimestamp":1745297189,"startTime":"0","endTime":"0","summary":"映恩生物-B今日盘中大涨15%，股价一度触及232.8港元，创上市以来新高。截至11时52分，该股涨幅收窄至15%，报230.2港元，成交额超1.75亿港元。国泰海通证券近期发布研报，给予映恩生物-B\"增持\"评级，目标价300.70港元。此外，映恩生物产品管线丰富，ADC布局持续扩容，预计2025-2027年收入将稳步增长。券商的积极评级进一步提振了投资者信心，推动股价创下新高。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09606"],"gpt_icon":0},{"id":"2529318988","title":"港股异动 | 映恩生物-B(09606)涨超16%创新高 公司聚焦ADC新药研发 核心产品初步展现治疗潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2529318988","media":"智通财经网","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529318988?lang=zh_cn&edition=full","pubTime":"2025-04-22 11:58","pubTimestamp":1745294280,"startTime":"0","endTime":"0","summary":"映恩生物-B午前涨超16%，高见232.8港元，创上市新高。截至发稿，涨13.2%，报226.4港元，成交额1.75亿港元。公开资料显示，映恩生物是全球抗体偶联药物领域的关键领跑者，致力于为癌症和自身免疫性疾病等患者研发ADC创新药物。公司拥有自主研发的两款核心产品，此外，公司有五项处于临床阶段的资产已获得美国食品药品管理局及中国国家药品监督管理局的研究用新药批准。国泰海通发布研报称，公司聚焦ADC新药研发，产品达成多项License-out对外授权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-22/doc-inetzepc5545457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4231","09606","BK4080","ADC"],"gpt_icon":1},{"id":"2529844691","title":"国泰海通：首予映恩生物-B(09606)“增持”评级 目标价300.70港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529844691","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529844691?lang=zh_cn&edition=full","pubTime":"2025-04-21 14:25","pubTimestamp":1745216757,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国泰海通发布研报称，首次覆盖映恩生物-B，给予“增持”评级。预计2025-2027年收入16.00/19.76/22.07亿元，综合绝对估值法及相对估值法，给予目标价300.70港元/股。国泰海通主要观点如下：DB-1303：对标Enhertu更优，全球领先跟进。HER2ADC已成为HER2+BC等领域的重要治疗手段，Enhertu在临床持续取得突破，正在引领临床用药迭代。风险调整后预计国内峰值有望达26亿元、美国峰值有望达16亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1281412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606"],"gpt_icon":1},{"id":"2527534280","title":"创下2022年以来18A融资规模新纪录，ADC独角兽映恩生物-B(09606)强势登陆港股","url":"https://stock-news.laohu8.com/highlight/detail?id=2527534280","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527534280?lang=zh_cn&edition=full","pubTime":"2025-04-16 12:09","pubTimestamp":1744776596,"startTime":"0","endTime":"0","summary":"坐拥自2022年以来18A生物科技板块内最大融资规模，暂居2025年港股IPO首日涨幅榜榜首......映恩生物-B凭借上述成绩，完成了从“国内ADC黑马”向“港股18A明星标的”的华丽转身。自2023年以来，映恩生物先后与BioNTech、百济神州、Adcendo、GSK、Avenzo、三生制药等国内外顶尖药企达成多项BD交易，总价值超60亿美元，助力公司成为国产ADC独角兽与出海“生力军”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1279367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["HSTECH","BK4614","ADC","BK4231","YANG","BK4080","09606"],"gpt_icon":1},{"id":"2527477255","title":"映恩生物登陆港交所首日大涨116.70%；百利天恒第10款ADC获批临床试验 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2527477255","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527477255?lang=zh_cn&edition=full","pubTime":"2025-04-16 07:40","pubTimestamp":1744760413,"startTime":"0","endTime":"0","summary":"NO.1映恩生物登陆港交所首日大涨116.70%4月15日，映恩生物正式在港交所挂牌，截至收盘股价大涨116.70%。公司本次IPO（首次公开发行）认购募资总额为2.1亿美元，约合人民币15.4亿元，刷新了2022年以来港股18A生物科技公司的融资纪录。资料显示，映恩生物成立于2019年，主要研发创新抗体偶联药物（ADC），用于治疗癌症、自身免疫性疾病等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504163377896945.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504163377896945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1576","BK1141","03347","BK1583","BK1161","BK4231","BK4080","09939","09606","ADC","BK1574"],"gpt_icon":1},{"id":"2527419593","title":"映恩生物港股上市首日收涨116.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527419593","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527419593?lang=zh_cn&edition=full","pubTime":"2025-04-15 20:57","pubTimestamp":1744721869,"startTime":"0","endTime":"0","summary":"北京商报讯（记者丁宁）4月15日，映恩生物（09606.HK）登录港交所，上市首日收涨116.7%，收盘价为205港元/股，总市值为175.1亿港元。招股书显示，映恩生物是一家专注于抗体偶联药物（ADC）研发的全球领跑企业，聚焦癌症及自身免疫性疾病领域。公司依托自主研发的四大技术平台，构建了差异化显著的创新管线，涵盖12款自主研发的ADC候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504153377602771.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504153377602771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["YANG","09606","BK4614","HSTECH"],"gpt_icon":0},{"id":"2527419596","title":"映恩生物上市首日涨超110%，每手赚上万港元 董事会主席朱忠远：虽三四年未融资，但是公司现金越来越多","url":"https://stock-news.laohu8.com/highlight/detail?id=2527419596","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527419596?lang=zh_cn&edition=full","pubTime":"2025-04-15 20:46","pubTimestamp":1744721219,"startTime":"0","endTime":"0","summary":"4月15日，映恩生物-B（HK09606，股价205港元，市值175.1亿港元）在港交所挂牌上市，这是港交所2022年以来融资规模最大的“18A”生物科技上市公司（指适用港交所上市规则第18A章的公司）。映恩生物每股定价94.6港元，共发行1733.23万股。上市首日开盘后，映恩生物一路走高，盘中最高涨幅曾超过130%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504153377600285.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504153377600285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09606"],"gpt_icon":1},{"id":"2527195974","title":"映恩生物首日暴涨116%：从“破发潮”到大涨，港股18A企业现反转信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2527195974","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527195974?lang=zh_cn&edition=full","pubTime":"2025-04-15 20:44","pubTimestamp":1744721065,"startTime":"0","endTime":"0","summary":"尽管市场走势疲软，但ADC（抗体偶联药物）龙头企业映恩生物(09606.HK)上市首日仍然大涨。4月15日，映恩生物(09606.HK)在港交所主板挂牌上市，当天报收于205港元，首日涨幅超过116%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504153377599531.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504153377599531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4614","09606","YANG","HSTECH"],"gpt_icon":1},{"id":"2527428573","title":"映恩生物暴涨116%，赛诺菲、BMS新药研究折戟","url":"https://stock-news.laohu8.com/highlight/detail?id=2527428573","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527428573?lang=zh_cn&edition=full","pubTime":"2025-04-15 19:34","pubTimestamp":1744716855,"startTime":"0","endTime":"0","summary":"映恩生物正式登陆港交所4月15日，ADC明星企业映恩生物正式登陆港交所，全球发售股份定价为每股94.6港元，开盘价为181港元，截至收盘，映恩生物每股报205港元，大涨116%，总市值约170.5亿港元。截至目前，映恩生物尚未获得任何候选药物的上市批准，亦未从产品销售中获得任何收入。BMS此前预计，如果Ⅲ期试验成功，Camzyos有望在2026年获批新适应症，并在2029年实现40亿美元的峰值销售额。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415194521a6bb2c13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415194521a6bb2c13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606"],"gpt_icon":1},{"id":"2527463916","title":"港股收盘(04.15) | 恒指收涨0.23% 大消费股表现活跃 映恩生物-B(09606)首挂飙升116%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527463916","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527463916?lang=zh_cn&edition=full","pubTime":"2025-04-15 16:39","pubTimestamp":1744706361,"startTime":"0","endTime":"0","summary":"截止收盘，恒生指数涨0.23%或48.87点，报21466.27点，全日成交额1850.64亿港元；恒生国企指数涨0.21%，报7982.88点；恒生科技指数跌0.67%，报4981.6点。截至收盘，跌4.53%，报45.35港元，成交额62.32亿港元，拖累恒指15.99点。美国特朗普政府正以威胁国家安全为由，启动对半导体和药品进口的调查。热门异动股1. 映恩生物-B首挂上市。截至收盘，涨4.57%，报70.9港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0488056044.USD","LU1328615791.USD","HSTECH","BK1549","LU0384037296.USD","LU0211977185.USD","LU0173614495.USD","BK1607","HSI","BK1523","BK1604","BK1526","YANG","LU2039709279.SGD","BK1504","BK4614","02833","LU0149534421.HKD","LU0607220059.USD","LU0593848301.USD","01458","LU1880383366.USD","BK1172","LU0594300419.USD","000997.SH","LU1048596156.SGD","513600","LU0348784397.USD","01478","HHImain","BK1589","LU0307460666.USD","LU0348783233.USD","LU0821914370.USD","LU0588546209.SGD","IE0034224299.USD","LU1166156734.SGD","LU1224709979.USD","LU0650527681.SGD","00027","09606","BK1555","MCHmain","LU0737861699.HKD","LU0140636845.USD","BK1240","01918"],"gpt_icon":1},{"id":"2527345054","title":"【新股IPO】映恩生物(09606)首挂收报205港元 较招股价高116.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527345054","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527345054?lang=zh_cn&edition=full","pubTime":"2025-04-15 16:14","pubTimestamp":1744704881,"startTime":"0","endTime":"0","summary":"金吾财讯 | 映恩生物(09606)首挂收报205港元，较招股价高116.7%，全日成交1082.52万股，成交额20.3亿港元，不计手续费，每手100股，账面赚11040港元。该股早盘开报181港元，较招股价高91.33%，亦为全日低点，最高见222港元。最新总市值170.51亿港元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20220324/M2U4NDlhMmZjNTFjY2Q0M2EzMzMyMTg5Mjc0MzM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/M2U4NDlhMmZjNTFjY2Q0M2EzMzMyMTg5Mjc0MzM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1957245","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"gpt_icon":0},{"id":"2527452883","title":"港股收盘，恒指收涨0.23%，恒生科技指数收跌0.67%，映恩生物(09606.HK)上市首日收涨116.70%，中芯国","url":"https://stock-news.laohu8.com/highlight/detail?id=2527452883","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527452883?lang=zh_cn&edition=full","pubTime":"2025-04-15 16:08","pubTimestamp":1744704527,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["HHImain","688981","MHImain","MCHmain","YANG","02833","BK1526","09606","BK1610","LU1064131003.USD","BK1607","HSI","00981","513600","HSCEI","HSTECH","LU2148510915.USD","SGXZ81163826.USD","BK1163","BK4614","BK1614","07226","BK0214","SGXZ49509284.SGD","LU1064130708.USD","HSImain"],"gpt_icon":0},{"id":"2527285744","title":"映恩生物正式挂牌港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2527285744","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527285744?lang=zh_cn&edition=full","pubTime":"2025-04-15 15:08","pubTimestamp":1744700897,"startTime":"0","endTime":"0","summary":"观点网讯：4月15日，映恩生物Duality Biotherapeutics, Inc.在香港联合交易所主板成功挂牌上市。映恩生物此次招股公开发售部分获115.14倍认购，国际发售部分获13.52倍认购。映恩生物此次IPO引入15名基石投资者，合共认购534.18万股发售股份，包括BioNTech、LAV Star等。截至最后实际可行日期，映恩生物在17个国家的230多个临床试验中心拥有七项全球多区域临床试验，已有2,000多名患者入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041515122497384778&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041515122497384778&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606"],"gpt_icon":1},{"id":"2527484547","title":"港股午评：恒指横盘震荡调整 食品饮料等消费板块表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2527484547","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527484547?lang=zh_cn&edition=full","pubTime":"2025-04-15 12:03","pubTimestamp":1744689805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1618","LU2148510915.USD","HSCEI","HXXD.SI","YANG","LU1956131251.USD","LU0359201612.USD","LU1868837565.USD","MCHmain","LU0499858438.USD","LU0348816934.USD","01458","09606","81810","HSTECH","LU0918141705.HKD","BK1614","BK1610","LU0052750758.USD","LU1981816686.USD","000807.SH","HSI","BK1521","XIACY","LU1023057109.AUD","BK1549","01810","HHImain","LU0700851271.USD","159843","00981","LU0593848301.USD","LU0918141887.USD","BK1526","BK1163","LU0327786744.USD","513600","02833","159582","LU1961090484.USD","LU0540923850.HKD","MHImain","HSImain","LU0797268264.HKD","LU1770036033.HKD","LU0235996351.USD","LU2097828474.EUR","688981","IE0034224299.USD","07226"],"gpt_icon":0},{"id":"2527484571","title":"港股午评|恒生指数早盘涨0.19%       食品饮料股走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2527484571","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527484571?lang=zh_cn&edition=full","pubTime":"2025-04-15 12:00","pubTimestamp":1744689626,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数涨0.19%，涨40点，报21457点；恒生科技指数跌0.91%。港股早盘成交1088亿港元。食品饮料股走高，市场风险偏好回落叠加内需预期提振，机构指食饮配置价值凸显。华润饮料涨4.95%，贸易冲突背景下内需重获重视，饮料业务有望保持高增速。名创优品早盘涨2.87%，机构称公司一季度同店环比改善，供应链多元化应对风险。报道称，这种豁免可能是短暂的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000807.SH","MCHmain","BK1241","02255","BK1200","HSTECH","159843","02833","513600","BK4614","HSI","HHImain","09606","YANG","02460"],"gpt_icon":1},{"id":"2527883364","title":"【新股IPO】映恩生物(09606) 布局ADC领域全球化商业模式  首日盘中暴涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2527883364","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527883364?lang=zh_cn&edition=full","pubTime":"2025-04-15 11:13","pubTimestamp":1744686831,"startTime":"0","endTime":"0","summary":"金吾财讯|映恩生物(09606)上市首日盘中暴涨，最高至132.56%，每股222港元。早盘持续高位，截止发稿报208.8港元，涨幅达120.72%。昨日暗盘收盘亦大涨87.10%，报177.00港元，不计手续费，每手赚8240港元。据悉，映恩生物在ADC领域的全球化商业模式取得了显著的成效。从技术平台的构建到研发管线的布局，从全球授权合作到全球临床协同，映恩生物形成了一个完整的全球化商业闭环。已先后与BioNTech、百济神州、葛兰素史克、Avenzo等国际知名药企达成授权出海合作，交易总金额超过60亿美元，其中已经收到的预付款和商业化里程碑约5亿美元。","market":"fut","thumbnail":"https://static.szfiu.com/news/20220324/OWMzMDQ5MTY2NDM3ODU0ODM5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/OWMzMDQ5MTY2NDM3ODU0ODM5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1957215","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","ADC","09606","BK4080"],"gpt_icon":0},{"id":"2527285784","title":"映恩生物港股上市 募资15亿港元加速创新抗体药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2527285784","media":"iDoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527285784?lang=zh_cn&edition=full","pubTime":"2025-04-15 10:24","pubTimestamp":1744683842,"startTime":"0","endTime":"0","summary":"4月15日，专注于肿瘤及自身免疫疾病抗体药物研发的映恩生物正式登陆港交所，发行价为每股94.6港元。此次上市全球发售净筹资约15.13亿港元，资金将用于推动其创新药管线研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041510413794d59a1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041510413794d59a1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["07226","HSTECH","09606"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dualitybiologics.com","stockEarnings":[{"period":"1week","weight":0.1677},{"period":"1month","weight":1.3108},{"period":"ytd","weight":1.3108}],"compareEarnings":[{"period":"1week","weight":0.0482},{"period":"1month","weight":-0.0767},{"period":"3month","weight":0.1204},{"period":"6month","weight":0.072},{"period":"1year","weight":0.3116},{"period":"ytd","weight":0.1003}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物。该公司的主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310、DB-1305/BNT325、DB-1419和DB-2304。该公司的产品主要用于靶向治疗子宫内膜癌（EC）、乳腺癌（BC）、小细胞肺癌（SCLC）、去势抵抗性前列腺癌（CRPC）、食管鳞状细胞癌（ESCC）及头颈部鳞状细胞癌（HNSCC）。该公司主要在国内和国外市场开展业务。","exchange":"SEHK","name":"映恩生物-B","nameEN":"DUALITYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"映恩生物-B,09606,映恩生物-B股票,映恩生物-B股票老虎,映恩生物-B股票老虎国际,映恩生物-B行情,映恩生物-B股票行情,映恩生物-B股价,映恩生物-B股市,映恩生物-B股票价格,映恩生物-B股票交易,映恩生物-B股票购买,映恩生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}